Format

Send to

Choose Destination
Methods Enzymol. 2014;546:119-38. doi: 10.1016/B978-0-12-801185-0.00006-4.

Genome editing in human stem cells.

Author information

1
Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
2
Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: sbyrne@genetics.med.harvard.edu.

Abstract

The use of custom-engineered sequence-specific nucleases (including CRISPR/Cas9, ZFN, and TALEN) allows genetic changes in human cells to be easily made with much greater efficiency and precision than before. Engineered double-stranded DNA breaks can efficiently disrupt genes, or, with the right donor vector, engineer point mutations and gene insertions. However, a number of design considerations should be taken into account to ensure maximum gene targeting efficiency and specificity. This is especially true when engineering human embryonic stem or induced pluripotent stem cells (iPSCs), which are more difficult to transfect and less resilient to DNA damage than immortalized tumor cell lines. Here, we describe a protocol for easily engineering genetic changes in human iPSCs, through which we typically achieve targeting efficiencies between 1% and 10% without any subsequent selection steps. Since this protocol only uses the simple transient transfection of plasmids and/or single-stranded oligonucleotides, most labs will easily be able to perform it. We also describe strategies for identifying, cloning, and genotyping successfully edited cells, and how to design the optimal sgRNA target sites and donor vectors. Finally, we discuss alternative methods for gene editing including viral delivery vectors, Cas9 nickases, and orthogonal Cas9 systems.

KEYWORDS:

CRISPR; Cas9 nuclease; Gene targeting; Human genome engineering; Induced pluripotent stem cells; Transfection

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center